Brief: Alterity Therapeutics Reports Positive Efficacy Data For Ath434 In A Primate Model Of Parkinson's Disease
04/12/2023 11:43
Dec 4 (Reuters) - Alterity Therapeutics Ltd ATH.AX :
* ALTERITY THERAPEUTICS REPORTS POSITIVE EFFICACY DATA FOR
ATH434
IN A PRIMATE MODEL OF PARKINSON'S DISEASE
* ALTERITY THERAPEUTICS LTD - ATH434 IMPROVED MOTOR
PERFORMANCE
AND GENERAL FUNCTION
Source text for Eikon: ID:
Further company coverage: ATH.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alterity Therapeutics
See all newsBrief: Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy
Brief: Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program
Brief: Alterity Therapeutics Says Julian Barbaczy Appointed Non-Exec Chair
Brief: Alterity Therapeutics Raises A$20.0 Million In Strategic Placement
Brief: Alterity Therapeutics Ltd Raises A$20 Million In Capital